Quantitative detection of lac-Z-transfected CC531 colon carcinoma cells in an orthotopic rat liver metastasis model

Clinical and Experimental Metastasis

Volumn 17, Issue 5, 1999, Pages 369-376

  Wittmer, Axel ^a   Khazaie, Khashayarsha ^a   Berger, Martin R ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Beta galactosidase; CC531; Chemiluminescence; Colon cancer; Liver metastasis

Indexed keywords

BETA GALACTOSIDASE; MATRIGEL;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOMA CELL; CHEMOLUMINESCENCE; COLON CARCINOMA; CONTROLLED STUDY; CYTOSTASIS; EXPERIMENTAL MODEL; FACILITATION; GENETIC TRANSFECTION; IMMUNOGENICITY; LIVER METASTASIS; MARKER GENE; NONHUMAN; QUANTITATIVE ASSAY; RAT; TUMOR GROWTH;

ANIMALS; BETA-GALACTOSIDASE; COLONIC NEOPLASMS; LIVER NEOPLASMS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RATS; TRANSFECTION;

EID: 0033382034     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006643831825     Document Type: Article

References (39)

1. 1. Van Triest B, Van Groeningen CJ, Pinedo HM. Treatment of colorectal cancer metastases confined to the liver. Eur J Cancer 1995; 31A: 1193-7.
2. 2. Boring CC, Squires TS, Tang T. Cancer statistics. Cancer J Clin 1991; 41: 19-36.
3. 3. Bosman FT. Prognostic value of pathological characteristics of colorectal cancer. Eur J Cancer 1995; 31A: 1216-21.
4. 4. Verdecchia A, De Angels R, Capocaccia R et al. The cure for colon cancer: Results from the Eurocare study. Int J Cancer 1998; 77: 322-9
5. 5. Borner M, Maurer CH. Die adjuvante Therapie des kolorektalen Karzinoms-Stand 1998. Schweiz med Wochenschr 1998; 128: 763-9.
6. 6. Gilbert HA, Kagan AR. Metastases: Incidence, detection, and evaluation without histologic confirmation. In Weiss L (ed): Fundamental Aspects of Metastasis. Amsterdam: North-Holland 1976; 385-405.
7. 7. Kemeny N, Conti JA, Sigurdson E et al. A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. A potential adjuvant program after resection of colorectal hepatic metastases. Cancer 1993; 71: 1964-71.
8. 8. Meta-Analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996; 88: 252-8.
9. 9. Pajkos G, Szentpetery L, Kristo K, Izso J. Combined therapy of metastatic liver neoplasms: intrahepatic chemoembolisalion and systemic chemotherapy. Orv Hetil 1998; 139: 1013-7.
10. 10. Swiss Group for Clinical Cancer Research. Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Lancet 1995; 345: 349-53.
11. 11. Liver Infusion Meta-Analysis Group. J Natl Cancer Inst 1997; 89: 497-505.
12. 12. Folkman-J. Anti-Angiogenesis: New concept for therapy of solid tumors. Ann Surg 1972; 175: 409-16.
13. 13. Folkman-J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
14. 14. Venditti JM, Wesley RA, Plowman J. Current NCI preclinical antitumor screening in vivo: Results of tumour panel screening, 1976-1982, and future directions. Adv Pharmacol Chemother 1982; 20: 1-20.
15. 15. Thomas C, Nijenhuis AM, Timens W et al. Liver metastases model of colon cancer in the rat: Immunhistochemical characterisation. Invasion Metatasis 1993; 13: 102-12.
16. 16. Griffini P, Smorenburg SM, Verbeek FJ, Van Noorden CJF. Three-dimensional reconstruction of colon carcinoma metastases in the liver. J Microscopy 1997; 187: 12-21.
17. 17. Griffini P, Smorenburg SM, Vogels IM et al. Kupffer cells and pit cells are not effective in the defense against experimentally induced colon carcinoma metastases in rat liver. Clin Exp Metastasis 1996; 14: 367-80.
18. 18. Fukumura D, Yuan F, Monsky WL et al. Effect of the host microenvironment on microcirculation of human colon adenocarcinoma. Am J Pathol 1997; 151(3): 679-88.
19. 19. Bartkowski R, Berger MR, Aguiar JLA et al. Experiments on the toxicity of locoregional chemotherapy of liver tumors with 5-fluoro-2′ deoxyuridine (FUDR) and 5-fluoruracil (5-FU) in an animal model. J Cancer Res Clin Oncol 1986; 111: 42-6.
20. 20. Kamphorst EJ, Bödecker H, Koroma S et al. New superselective arterial (chemo-) embolization of the rat liver. Lab Animal Sci 1999; 49: 216-9.
21. 21. Aguiar JL, Bartkowski R, Berger MR et al. Feasible model of locoregional and systemic longterm administration of drugs and concomitant blood sampeling in Sprague-Dawley rats. J Cancer Res Clin Oncol 1987; 113: 27-30.
22. 22. Zhang L, Hellstrom KE, Chen L. Luciferase activity as a marker of tumour burden and as an indicator of tumour response to antineoplastic therapy in vivo. Clin Exp Metastasis 1994; 12: 87-92.
23. 23. Chishima T, Miyagi Y, Wang X et al. Cancer invasion and micrometastases visualized in liver tissue by green fluorescent protein expression. Cancer Res 1997; 57: 2042-7.
24. 24. Dooly TP, Stamp-Cole M, Ouding RJ. Evaluation of a nude mouse tumour model using beta-galactosidase-expressing melanoma cells. Lab Anim Sci 1993; 43: 48-57.
25. 25. Marquet RL, Westbrock DL, Jeekel D. Interferon treatment of a transplantable rat colon adenocarcinoma: Importance of tumour site. Int J Cancer 1984; 33: 689-92.
26. 26. Ferry N, Duplessis O, Houssin O et al. Retroviral-mediated gene transfer into hepatocytes in vivo. Proc Natl Acad Sci USA 1991; 88: 8377-81.
27. 27. Nolan GP, Fiering S, Nicolas JF, Herzenberg LA. Fluorescence-activated cell analysis and sorting of viable mammalian cells based on beta-D-galactosidase activity after transduction of Escherichia coli lac-Z. Proc Natl Acad Sci USA 1988; 85: 2603-7.
28. 28. Konstantinov SM, Topashka-Ancheva M, Benner A, Berger MR. Alkylphosphocolines: Effects on human leukemic cell lines and normal bone marrow cells. Int J Cancer 1988; 77: 778-86.
29. 29. Sanes JR, Rubenstein JLR, Nicolas JF. Use of recombinant retrovirus to study post-implantation cell lineage in mouse embryos. EMBO J 1986; 5: 3133-42.
30. 30. O'Conner KL, Culp LA. Quantitation of two histochemical markers in the same extract using chemiluminescent substrates. BioTechniques 1994; 17: 502-9.
31. 31. Dunn OJ. Multiple comparison using rank sums. Technometrics 1964; 6: 241-52.
32. 32. Hagenaars M, Ensink NG, Koelemij R et al. Regional administration of natural killer cells in a rat hepatic metastases model results in better tumour infiltration and anti-tumour response than systemic administration. Int J Cancer 1998; 75: 233-8.
33. 33. Price JE. Metastasis from human breast cancer cell lines. Breast Cancer Res Treat 1996; 39: 93-102.
34. 34. Van De Vrie W, Marquet RL, Eggermont AM. Cyclosporin A enhances locoregional metastases of the CC531 rat colon tumour. J Cancer Res Clin Oncol 1997; 123: 21-4.
35. 35. Krüger A, Schirrmacher V, Khokha R. The bacterial lac-Z Gene: An important tool for metastasis research and evaluation of new cancer therapies. Cancer Met Rev 1999 (in press).
36. 36. Khazaie K, Prifti S, Beckhove P et al. Persistence of dormant tumour cells in the bone marrow of tumour cell-vaccinated mice correlates with long-term immunological protection. Proc Natl Acad Sci USA 1994; 91: 7430-4.
37. 37. Müller M, Gounari F, Prifti S et al. Eblac-Z, tumour dormancy in bone marrow and lymph nodes: Active control of proliferating tumour cells by CD8+ immune T cells. Cancer Res 1998; 58: 5439-16.
38. 38. Wyrick BJ, Ozawa T, Lamborn KR et al. Effects of matrigel on the SF-767 malignant glioma athymic mouse tumour model. Anticancer Res 1997; 17: 2419-26.
39. 39. Bonfil RD, Vinyals A, Bustuoabad OD et al. Stimulation of angiogenesis as an explanation of matrigel enhanced tumorigenicity. Int J Cancer 1994; 58: 233-9.